(Reuters) - NEW YORK, June 27 - Merck & Co. on Wednesday said U.S. regulators will review its experimental HIV drug Isentress on a priority basis, and that it anticipates a decision on the first in a new class of medicines by mid-October.
Merck said the drug, if approved, would be used alongside standard oral HIV drugs among patients that were no longer adequately protected by their current treatments because of viral resistance.
Read more at Reuters.com Government Filings News
Merck said the drug, if approved, would be used alongside standard oral HIV drugs among patients that were no longer adequately protected by their current treatments because of viral resistance.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment